- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Therapeutic Areas
Publications and Presentations
Check out our publications and poster presentations.
November 2021
November 2021
A Phase 1b Randomized, Double-blind, Placebo-controlled, Dose Escalation Trial of CB-280, an Arginase Inhibitor, in Patients With Cystic FibrosisNorth American Cystic Fibrosis Conference
September 2021
March 2021
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated ImmunotherapiesMolecular Cancer Therapeutics
January 2021
A Phase 1/2 Study of Safety and Efficacy of the Arginase Inhibitor INCB001158 Plus Chemotherapy in Patients With Advanced or Metastatic Biliary Tract CancersASCO Gastrointestinal Cancers Symposium
Our Pipeline
We are focused on novel treatments for
cancer and other life-threatening diseases.